secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001193125-25-110019
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Phase 3 EBO-301 misses primary endpoint; outlines boron pipeline milestones, cash runway into 2028
--------------------------------------------------------------------------------

- Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.
- Cash, cash equivalents & investments $78.5M as of March 31, 2025; cash runway extended into 2028.
- Initiated start up for Phase 1 study of AN2-502998 for chronic Chagas disease, expected completion in 2H25.
- Plans Phase 2 study for epetraborole in melioidosis in 2H25 aiming to reduce ~40% mortality.
- First oncology compounds from boron platform on track for development in 2H25, targeting ENPP1, PI3Kα.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/0001193125-25-110019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525110019/d116214d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-110019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer